Nature, 608(7921), E1-E10. Nature Publishing Group Nature, 608. Nature Publishing Group UPCommons. Portal del coneixement obert de la UPC Universitat Politècnica de Catalunya (UPC) Nature r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname COVID-19 Host Genetics Initiative, Hottenga, J J, Bartels, M, de Geus, E J C & Nivard, M 2022, ' A first update on mapping the human genetic architecture of COVID-19 ', Nature, vol. 608, no. 7921, pp. E1-E10 . https://doi.org/10.1038/s41586-022-04826-7 2022, ' A first update on mapping the human genetic architecture of COVID-19 ', Nature, vol. 608, no. 7921, pp. E1-E10 . https://doi.org/10.1038/s41586-022-04826-7
JAMA : the journal of the American Medical Association JAMA, 329(1), 39-51. American Medical Association Journal of the American Medical Association Journal of the American Medical Association, 2023, 329 (1), pp.39-51. ⟨10.1001/jama.2022.23257⟩ Jama : Journal of the American Medical Association, 329, 1, pp. 39-51 Higgins, A M, Berry, L R, Lorenzi, E, Murthy, S, McQuilten, Z, Mouncey, P R, Al-Beidh, F, Annane, D, Arabi, Y M, Beane, A, Van Bentum-Puijk, W, Bhimani, Z, Bonten, M J M, Bradbury, C A, Brunkhorst, F M, Burrell, A, Buzgau, A, Buxton, M, Charles, W N, Cove, M, Detry, M A, Estcourt, L J, Fagbodun, E O, Fitzgerald, M, Girard, T D, Goligher, E C, Goossens, H, Haniffa, R, Hills, T, Horvat, C M, Huang, D T, Ichihara, N, Lamontagne, F, Marshall, J C, McAuley, D F, McGlothlin, A, McGuinness, S P, McVerry, B J, Neal, M D, Nichol, A D, Parke, R L, Parker, J C, Parry-Billings, K, Peters, S E C, Reyes, L F, Rowan, K M, Saito, H, Santos, M S, Saunders, C T & Serpa-Neto, A 2023, ' Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial ', JAMA, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Bradbury, C A & Higgins, A M 2023, ' Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial ', JAMA-Journal of the American Medical Association, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Jama : Journal of the American Medical Association, 329, 39-51 JAMA
Lancet Gastroenterology & Hepatology, 7, 388-390 Méndez-Sánchez, N, Bugianesi, E, Gish, R G, Lammert, F, Tilg, H, Nguyen, M H, Sarin, S K, Fabrellas, N, Zelber-Sagi, S, Fan, J-G, Shiha, G, Targher, G, Zheng, M-H, Chan, W-K, Vinker, S, Kawaguchi, T, Castera, L, Yilmaz, Y, Korenjak, M, Spearman, C W, Ungan, M, Palmer, M, El-Shabrawi, M, Gruss, H-J, Dufour, J-F, Dhawan, A, Wedemeyer, H, George, J, Valenti, L, Fouad, Y, Romero-Gomez, M, Eslam, M & Global multi-stakeholder consensus on the redefinition of fatty liver disease 2022, ' Global multi-stakeholder endorsement of the MAFLD definition ', The Lancet. Gastroenterology & hepatology, vol. 7, no. 5, pp. 388-390 . https://doi.org/10.1016/S2468-1253(22)00062-0 The Lancet Gastroenterology & hepatology, Vol. 7, no.5, p. 388-390 (2022) Lancet gastroenterology & hepatology Lancet Gastroenterology & Hepatology, 7, 5, pp. 388-390